Xtant Medical Holdings, Inc. (XTNT) |
0.7 0 (0%)
|
02-02 14:44 |
Open: |
0.68 |
Pre. Close: |
0.7 |
High:
|
0.714 |
Low:
|
0.67 |
Volume:
|
12,881 |
Market Cap:
|
76(M) |
|
|
Technical analysis |
as of: 2023-02-02 3:16:13 PM |
Overall:
|
|
Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
Target: |
Six months: 0.84 One year: 0.98 |
Support: |
Support1: 0.62 Support2: 0.56 |
Resistance: |
Resistance1: 0.72 Resistance2: 0.84 |
Pivot: |
0.65  |
Moving Average: |
MA(5): 0.69 MA(20): 0.64 
MA(100): 0.65 MA(250): 0.61  |
MACD: |
MACD(12,26): 0 Signal(9): 0  |
Stochastic oscillator: |
%K(14,3): 87.1 %D(3): 85.9  |
RSI: |
RSI(14): 57.4 |
52-week: |
High: 0.92 Low: 0.43 |
Average Vol(K): |
3-Month: 34 (K) 10-Days: 30 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ XTNT ] has closed below upper band by 19.4%. Bollinger Bands are 0.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
0.72 - 0.72 |
0.72 - 0.73 |
Low:
|
0.69 - 0.69 |
0.69 - 0.7 |
Close:
|
0.69 - 0.7 |
0.7 - 0.71 |
|
Company Description |
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana. |
Headline News |
Mon, 09 Jan 2023 Xtant Medical Holdings (XTNT) Appoints Mark Schallenberger as COO - StreetInsider.com
Mon, 21 Nov 2022 Xtant Medical Honors Donor Hero Asante Contreras on the Donate Life Rose Parade® Float - Yahoo Finance
Thu, 03 Nov 2022 Xtant Medical Announces Third Quarter 2022 Financial Results - GlobeNewswire
Mon, 17 Oct 2022 The 1001 Imploded Stocks of 2022 (Down 80% or More)… So Far - WOLF STREET
Tue, 11 Oct 2022 Xtant Medical Announces Closing of Second Tranche of $9.75 ... - GlobeNewswire
Wed, 24 Aug 2022 Xtant Medical Announces $9.75 Million Private Investment - GlobeNewswire
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: AMEX |
Sector: Healthcare |
Industry: Medical Devices |
Shares Out. |
87 (M) |
Shares Float |
7 (M) |
% Held by Insiders
|
1 (%) |
% Held by Institutions
|
92.7 (%) |
Shares Short
|
127 (K) |
Shares Short P.Month
|
198 (K) |
Stock Financials |
EPS
|
-0.04 |
EPS Est Next Qtl
|
-0.24 |
EPS Est This Year
|
-1.29 |
EPS Est Next Year
|
-0.45 |
Book Value (p.s.)
|
0.37 |
Profit Margin (%)
|
-6 |
Operating Margin (%)
|
0.8 |
Return on Assets (ttm)
|
0.5 |
Return on Equity (ttm)
|
0 |
Qtrly Rev. Growth
|
-1.8 |
Gross Profit (p.s.)
|
0.39 |
Sales Per Share
|
0.63 |
EBITDA (p.s.)
|
0.02 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
1 (M) |
Levered Free Cash Flow
|
1 (M) |
Stock Valuations |
PE Ratio
|
-17.5 |
PEG Ratio
|
0 |
Price to Book value
|
1.84 |
Price to Sales
|
1.09 |
Price to Cash Flow
|
65.19 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|